The four biotech stories you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: Pharmaceuticals
STAT+: The new NIH director is walking a tightrope on Biden’s drug pricing vision
WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally…
Novartis reportedly decides to pass on Cytokinetics
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: New congressional bill would thwart patent thickets in order to speed generic drugs to market
In the latest bid to lower the cost of medicines, a new bill was introduced…
The highs — and lows — of JPM 2024 you should pay attention to
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
.jpg)
GLP-1 drugs not linked to suicidal thoughts, FDA’s early review finds
A preliminary evaluation by the Food and Drug Administration did not find evidence that GLP-1…
JPM Day 3 had a cautiously optimistic outlook
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
STAT+: Bayer’s promising menopause drug trial results highlight growing interest in long-neglected condition
More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two…
JPM Day 2 has arrived. Here are the can’t-miss moments of the event so far
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
Anthony Fauci talked Covid in Congress in a nine-hour, closed-door grilling — and that was just day one
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: GSK to acquire Aiolos Bio in $1.4 billion deal, picking up an experimental asthma drug
LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for…
This is the TLDR of JPM Day 1
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
STAT+: Walgreens isn’t acquiring anytime soon, per CEO
Between Walgreens’ earnings call last week and its J.P. Morgan Healthcare Conference presentation on Monday,…
STAT+: The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma
Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion,…
STAT+: GSK is replacing its popular Flovent inhaler with authorized generics, raising cost concerns for asthma patients
As of Jan. 1, thousands of asthma patients in the U.S. will no longer be…
At JPM, how much health policy talk should we expect?
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers
Several advocacy groups are blasting a Food and Drug Administration proposal to work with a…
Why CG Oncology will be the first test of 2024’s IPO waters
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Anavex’s slow journey to failure
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Consumer health advocate Sid Wolfe was a thorn in the side. We’re all the better as a result
The first phone call came some time in late 1996. “Ed, I’d like to introduce…
UnitedHealth’s rehab restrictions, Texas medical school drama, and health care’s biggest profits
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of…
An ugly fight over care for the poor in Texas
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: 3 health policies states are taking on in 2024
For most states, the new year means a new legislative session. STAT’s taking a look…
STAT+: What comes after Wegovy? The quest to eradicate obesity
About a decade ago, after becoming obese, Jacob Petersen lost weight so quickly that some…
STAT+: 3 FDA staffers to watch in 2024
WASHINGTON — The Food and Drug Administration has a lot on its plate in 2024…
STAT+: 3 issues to watch in pharma in 2024
As another year comes to an end and the world seems to hit the proverbial…
STAT+: Bristol Myers will pay $4.1 billion for cancer startup RayzeBio
Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into…
Morning Rounds: Our newsroom’s favorite stories of 2023
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
The clock is ticking, and cytokinetics is running out of December
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion
Bristol Myers Squibb said Friday that it will acquire Karuna Therapeutics, a developer of medicines…
Morning Rounds: Why health care costs are nearly a fifth of the GDP
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
BioMarin appeases an activist
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace
To ring the register, a pharmaceutical company may create a patent thicket, which involves filing…
STAT+: Medical marijuana companies are using pharma’s sales tactics with little of the same scrutiny
WASHINGTON — Medical marijuana companies sell medicine, just like pharmaceutical companies. But they’re not playing…
STAT+: Drugs are still mostly tested in white men. Will the FDA change that next year?
WASHINGTON — Sometime next year drug and medical device companies will have to tell the…
The biotech updates you need to read today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
What the new health counsels at FTC, DOJ, and HHS might do
Three major government agencies are adding new officials to investigate price-gouging in health care —…
Here are the worst biopharma CEOs of 2023
Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of…
The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Here are the best biopharma CEOs of 2023
It’s that time of the year again when I recognize the Best Biopharma CEO of…
STAT+: ‘We’ve exhausted all avenues’: A small biotech may give up on its ultra-rare disease drug over frustration with FDA
Jamie Dubuque faces the future with a mixture of gratitude and trepidation. Her son, Declan,…
FDA chastens pet companies over antibiotics
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: European regulators endorse Casgevy, paving way for approval of CRISPR-based therapy
LONDON — The world’s first medicine based on the genome-editing technology CRISPR will almost certainly…
Morning Rounds: Teen pregnancies down, but remain higher in the U.S.
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
STAT+: Jay Bradner, former Novartis research leader, to head up Amgen’s scientific efforts
Jay Bradner, a former top research leader at Novartis, is joining Amgen as its new…
Is it time to worry about Moderna?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
A plot to solve the ‘whack-a-mole’ of drug discovery
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pfizer says 2024 profits will fall far below expectations
Pfizer said Wednesday that its 2024 profits would fall far below investor expectations, leading shares…
Morning Rounds: Can you take GLP-1 drugs during pregnancy?
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
Morning Rounds: Preterm birth rates vary across the U.S., with the highest in the Southeast
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…